{"success":true,"data":{"pressRelease":{"id":"183653","rtpr_id":"nPnbcYmlka-20261029","ticker":"EVO","exchange":"NASDAQ","all_tickers":["EVO","EVTG"],"title":"Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026","author":"PR Newswire","published_at":"2026-10-29T07:00:45.863Z","article_body":"Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026\nPR Newswire\n\nHAMBURG, Germany, Oct. 29, 2026\n\nHAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO)\n(Frankfurt Prime Standard: EVT) will hold a webcast and conference call to\nannounce its financial results for the first nine months 2026 and provide a\nbusiness update on Thursday, November 5, 2026. The conference call will be\nheld in English.\n\nWebcast details\n\nDate: Thursday, November 5, 2026\nTime: 2.00 pm CET (1.00 pm GMT, 8.00 am EST)\n\nTo join the audio webcast and to access the presentation slides, please\nregister via this link (https://www.webcast-eqs.com/evotec-2026-q3) .\nThe on-demand version of the webcast will be available on our website:\nwww.evotec.com\n(https://www.evotec.com/ir-news/investor-relations/financial-publications) .\n\nConference call details\n\nTo join the conference call, please pre-register via this link\n(https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=9904737&linkSecurityString=1c57a074c2)\n. You will then receive a confirmation email with dedicated dial-in details\nsuch as telephone number, access code and PIN to access the call.\n\nA simultaneous slide presentation for participants dialing in via phone is\navailable under this link\n(https://www.webcast-eqs.com/evotec-2026-q3/no-audio) .\n\nAbout Evotec SE\n\nEvotec is a life science company that is pioneering the future of drug\ndiscovery and development. By integrating breakthrough science with AI-driven\ninnovation and advanced technologies, we accelerate the journey from concept\nto cure — faster, smarter, and with greater precision. Our expertise spans\nsmall molecules, biologics, cell therapies and associated modalities,\nsupported by proprietary platforms such as Molecular Patient Databases,\nPanOmics and iPSC-based disease modeling. With flexible partnering models\ntailored to our customers' needs, we work with all Top 20 Pharma companies,\nover 800 biotechs, academic institutions, and healthcare stakeholders. Our\nofferings range from standalone services to fully integrated R&D programs\nand long-term strategic partnerships, combining scientific excellence with\noperational agility. Through Just – Evotec Biologics, we redefine biologics\ndevelopment and manufacturing to improve accessibility and affordability. With\na strong portfolio of over 100 proprietary R&D assets, most of them being\nco-owned, we focus on key therapeutic areas including oncology, cardiovascular\nand metabolic diseases, neurology, and immunology. Evotec's global team of\naround 4,500 experts operates from sites in Europe and the U.S., offering\ncomplementary technologies and services as synergistic centers of excellence.\nLearn more at www.evotec.com (http://www.evotec.com/) and follow us\non LinkedIn (https://www.linkedin.com/company/evotec) and X/Twitter @Evotec\n(https://twitter.com/evotec) .\n\nForward-looking statements\n\nThis announcement contains forward-looking statements concerning future\nevents, including the proposed offering and listing of Evotec's securities.\nWords such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"should,\" \"target,\" \"would\" and\nvariations of such words and similar expressions are intended to identify\nforward-looking statements. Such statements include comments regarding\nEvotec's expectations for revenues, Group EBITDA and unpartnered R&D\nexpenses. These forward-looking statements are based on the information\navailable to, and the expectations and assumptions deemed reasonable by Evotec\nat the time these statements were made. No assurance can be given that such\nexpectations will prove to have been correct. These statements involve known\nand unknown risks and are based upon a number of assumptions and estimates,\nwhich are inherently subject to significant uncertainties and contingencies,\nmany of which are beyond the control of Evotec. Evotec expressly disclaims any\nobligations or undertaking to release publicly any updates or revisions to any\nforward-looking statements contained herein to reflect any change in Evotec's\nexpectations with respect thereto or any change in events, conditions or\ncircumstances on which any statement is based.\n\nInvestor Relations and Media Contact\n\nDr. Sarah Fakih\nEVP Head of Global Communications & Investor Relations\nSarah.Fakih@evotec.com (mailto:Sarah.Fakih@evotec.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/evotec-se-to-announce-results-for-the-first-nine-months-2026-on-november-5-2026-302923251.html\n(https://www.prnewswire.com/news-releases/evotec-se-to-announce-results-for-the-first-nine-months-2026-on-november-5-2026-302923251.html)\n\nSOURCE Evotec SE\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbcYmlka-20261029","title":"Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026","author":"PR Newswire","ticker":"EVO","created":"2026-10-29T07:00:45.863Z","tickers":["EVO","EVTG"],"exchange":"NASDAQ","article_body":"Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026\nPR Newswire\n\nHAMBURG, Germany, Oct. 29, 2026\n\nHAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO)\n(Frankfurt Prime Standard: EVT) will hold a webcast and conference call to\nannounce its financial results for the first nine months 2026 and provide a\nbusiness update on Thursday, November 5, 2026. The conference call will be\nheld in English.\n\nWebcast details\n\nDate: Thursday, November 5, 2026\nTime: 2.00 pm CET (1.00 pm GMT, 8.00 am EST)\n\nTo join the audio webcast and to access the presentation slides, please\nregister via this link (https://www.webcast-eqs.com/evotec-2026-q3) .\nThe on-demand version of the webcast will be available on our website:\nwww.evotec.com\n(https://www.evotec.com/ir-news/investor-relations/financial-publications) .\n\nConference call details\n\nTo join the conference call, please pre-register via this link\n(https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=9904737&linkSecurityString=1c57a074c2)\n. You will then receive a confirmation email with dedicated dial-in details\nsuch as telephone number, access code and PIN to access the call.\n\nA simultaneous slide presentation for participants dialing in via phone is\navailable under this link\n(https://www.webcast-eqs.com/evotec-2026-q3/no-audio) .\n\nAbout Evotec SE\n\nEvotec is a life science company that is pioneering the future of drug\ndiscovery and development. By integrating breakthrough science with AI-driven\ninnovation and advanced technologies, we accelerate the journey from concept\nto cure — faster, smarter, and with greater precision. Our expertise spans\nsmall molecules, biologics, cell therapies and associated modalities,\nsupported by proprietary platforms such as Molecular Patient Databases,\nPanOmics and iPSC-based disease modeling. With flexible partnering models\ntailored to our customers' needs, we work with all Top 20 Pharma companies,\nover 800 biotechs, academic institutions, and healthcare stakeholders. Our\nofferings range from standalone services to fully integrated R&D programs\nand long-term strategic partnerships, combining scientific excellence with\noperational agility. Through Just – Evotec Biologics, we redefine biologics\ndevelopment and manufacturing to improve accessibility and affordability. With\na strong portfolio of over 100 proprietary R&D assets, most of them being\nco-owned, we focus on key therapeutic areas including oncology, cardiovascular\nand metabolic diseases, neurology, and immunology. Evotec's global team of\naround 4,500 experts operates from sites in Europe and the U.S., offering\ncomplementary technologies and services as synergistic centers of excellence.\nLearn more at www.evotec.com (http://www.evotec.com/) and follow us\non LinkedIn (https://www.linkedin.com/company/evotec) and X/Twitter @Evotec\n(https://twitter.com/evotec) .\n\nForward-looking statements\n\nThis announcement contains forward-looking statements concerning future\nevents, including the proposed offering and listing of Evotec's securities.\nWords such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"should,\" \"target,\" \"would\" and\nvariations of such words and similar expressions are intended to identify\nforward-looking statements. Such statements include comments regarding\nEvotec's expectations for revenues, Group EBITDA and unpartnered R&D\nexpenses. These forward-looking statements are based on the information\navailable to, and the expectations and assumptions deemed reasonable by Evotec\nat the time these statements were made. No assurance can be given that such\nexpectations will prove to have been correct. These statements involve known\nand unknown risks and are based upon a number of assumptions and estimates,\nwhich are inherently subject to significant uncertainties and contingencies,\nmany of which are beyond the control of Evotec. Evotec expressly disclaims any\nobligations or undertaking to release publicly any updates or revisions to any\nforward-looking statements contained herein to reflect any change in Evotec's\nexpectations with respect thereto or any change in events, conditions or\ncircumstances on which any statement is based.\n\nInvestor Relations and Media Contact\n\nDr. Sarah Fakih\nEVP Head of Global Communications & Investor Relations\nSarah.Fakih@evotec.com (mailto:Sarah.Fakih@evotec.com)\n\n \n\nView original\ncontent:https://www.prnewswire.com/news-releases/evotec-se-to-announce-results-for-the-first-nine-months-2026-on-november-5-2026-302923251.html\n(https://www.prnewswire.com/news-releases/evotec-se-to-announce-results-for-the-first-nine-months-2026-on-november-5-2026-302923251.html)\n\nSOURCE Evotec SE\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-29T07:00:45.920809402Z","server_sent_at_ms":1793257245920},"received_at":"2026-10-29T07:00:45.972Z","source_url":"https://www.prnewswire.com/news-releases/evotec-se-to-announce-results-for-the-first-nine-months-2026-on-november-5-2026-302923251.html"},"analysis":{"id":"171405","press_release_id":"183653","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Evotec SE will announce results for the first nine months of 2026 and provide a business update on Thursday, November 5, 2026.\n\nThe results will be delivered via a webcast at 2.00 pm CET along with a conference call held in English; registration links and an on-demand replay are available on the company's website.\n\nThis is a scheduling notice only and contains no financial results or guidance.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar notice: Evotec 9M 2026 results call set for November 5 -- no actionable content until then."},"keyFigures":{},"namedEntities":{"people":[{"name":"Dr. Sarah Fakih","role":"EVP Head of Global Communications & Investor Relations"}],"products":[],"companies":[{"name":"Evotec SE","ticker":"EVO"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a scheduling notice for an upcoming earnings call/webcast with no financial results, guidance, or business developments disclosed."},"tickerRelevance":{"others":[],"primary":"EVO"},"globalImportance":8,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice-only","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Evotec SE will announce results for the first nine months of 2026 and provide a business update on Thursday, November 5, 2026.\n\nThe results will be delivered via a webcast at 2.00 pm CET along with a conference call held in English; registration links and an on-demand replay are available on the company's website.\n\nThis is a scheduling notice only and contains no financial results or guidance.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Sarah Fakih","role":"EVP Head of Global Communications & Investor Relations"}],"products":[],"companies":[{"name":"Evotec SE","ticker":"EVO"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-29T07:00:50.683Z","global_importance":8,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"earnings-date-notice-only","issuerAuthored":true}},"durationMs":4008,"modelName":"glm-5.3-flashx"}}